Using botulinum toxin for pelvic indications in women

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 49, Issue 4, 2009, Pages 352-357

  Rao, Archana ^a   Abbott, Jason ^a,b  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Botulinum toxin; Pelvic floor; Pelvic pain

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIBODY PRODUCTION; BLADDER TRAINING; CONSTIPATION; DEFECATION DISORDER; DISEASE ASSOCIATION; DRUG INDICATION; DYSPAREUNIA; FECES INCONTINENCE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OVERACTIVE BLADDER; PAIN ASSESSMENT; PELVIS FLOOR; PELVIS PAIN SYNDROME; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; URINE INCONTINENCE; URINE RETENTION; VAGINISM; VULVAR VESTIBULITIS;

BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; FEMALE; HUMANS; NEUROMUSCULAR AGENTS; PELVIC FLOOR; PELVIC PAIN; TREATMENT OUTCOME;

EID: 70350170537     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2009.01028.x     Document Type: Review

References (45)

1. Sinha D, Karri K, Arunkalaivanan A. Applications of botulinum toxin in urogynaecology. Eur J Obstet Gynaecol Reprod Biol 2007; 133: 4-11.
2. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol 2003; 44: 165-174.
3. Wollina U, Goldman A, Berger U, Abdel-Naser M. Esthetic and cosmetic dermatology. Dermatol Ther 2008; 21: 118-130.
4. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006; 9: 145-148.
5. Cantarella G, Berlusconi A, Maraschi B, Ghio A, Barbieri S. Botulinum toxin injection and airflow stability in spasmodic dysphonia. Otolaryngol Head Neck Surg 2006; 134: 419-423.
6. Radensky P, Archer J, Dournaux S, O'Brien C. The estimated cost of managing focal spasticity: A physician practice patterns survey. Neurorehabil Neural Repair 2001; 15: 57-68.
7. Cheng CM, Chen JS, Patel RP. Unlabelled uses of botulinum toxins: A review, part 2. Am J Health-Syst Pharm 2006; 63: 225-232.
8. Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. Br J Urol Int 2007; 100: 1302-1306.
9. Jarvis S, Abbott J, Lenart M, Steensma A, Vancaille T. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain as associated with spasm of the levator ani muscles. Aust N Z J Obstetrics Gynaecol 2004; 44: 46-50.
10. Abbott J, Jarvis S, Lyons S, Thomson A, Vancaille T. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: A randomized controlled trial. Obstet Gynecol 2006; 108: 915-923.
11. Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: An open-label, pilot study. J Reprod Med 2006; 51: 467-470.
12. Floyd ND, Kondylis L, Kondylis PD, Reilly JC. Chronic anal fissure: 1994 and a decade later - Are we doing better? Am J Surg 2006; 191: 344-348.
13. Maria G, Cadeddu C, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet type constipation. Am J Gastroenterol 2006; 101: 2570-2575.
14. Mathias S, Kupperman M, Liberman R, Lipschutz R, Steege J. Chronic pelvic pain: Prevalence, health related quality and economic correlates. Obstet Gynecol 1996; 87: 321-327.
15. Wissel J, Muller J, Dressnandt J et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000; 20: 44-49.
16. Brin M, Vapnek J. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252-253.
17. Milburn A, Reiter R, Rhomberg A. Multidisciplinary approach to chronic pelvic pain. Obstet Gynecol Clin North Am 1993; 20: 643-661.
18. Sator-Katzenschlager S, Scharbert G, Kress H et al. Chronic pelvic pain treated with gabapentin and amitriptyline: A randomized controlled pilot study. Wien Klin Wochenschr 2005; 117: 761-768.
19. Howard F. An evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: Placebo controlled studies. J Am Assoc Gynecol Laparosc 2000; 7: 477-488.
20. Binder W, Brin M, Blitzer A, Pogoda J. Botulinum toxin typeA (BOTOX) for treatment of migraine. Semin Cutan Med Surg 2001; 20: 93-100.
21. Foster L, Clapp L, Erikson M, Jabbar B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001; 56: 1290-1293.
22. Truong D, Duane D, Jankovic J et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20: 783-791.
23. Bertolasi L, Bottanelli M, Graziottin A. Dyspareunia, vaginismus, hyperactivity of the pelvic floor and botulin toxin: The neurologists role. Giornale Italiano di Ostetricia e Ginecologia 2006; 28: 264-268.
24. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104: 922-925.
25. Hundley A, Wu J, Visco A. A comparison of perineometer to brink score for assessment of pelvic floor muscle strength. Am J Obstet Gynecol 2005; 192: 1583-1591.
26. Westrom L, Willen R. Vestibular nerve proliferation in vulvar vestibulitis syndrome. Obstet Gynecol 1998; 91: 572-576.
27. Edwards L. New concepts in vulvodynia. Am J Obstet Gynecol 2003; 189: S24-S40.
28. Glazer H, Rodke G, Swencionis C. Treatment of vulvar vestibulitis syndrome with electromyographic biofeedback of pelvic floor musculature. J Reprod Med 1995; 40: 283-290.
29. Goldstein A, Marinoff S, Haefner H. Vulvodynia: Strategies for treatment. Clin Obstet Gynecol 2005; 48: 769-785.
30. Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007; 19: 84-87.
31. Garrigues V, Galvez C, Ortiz V. Prevalence of constipation: Agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population based survey in Spain. Am J Epidemiol 2004; 159: 520-526.
32. Gagliardi G, Pescatori M, Altomare D et al. Italian Society of Colo-Rectal Surgery (SICCR). Results, outcome predictors, and complications after stapled transanal rectal resection for obstructed defecation. Dis Colon Rectum 2008; 51: 186-195.
33. Naumann M, So Y, Argoff C et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidencebased review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707-1714.
34. Schurch B. Botulinum toxin for the management of bladder dysfunction. Drugs 2006; 66: 1301-1318. (Pubitemid 44246615)
35. Patel A, Patterson J, Chapple C. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006; 50: 684-709.
36. Abrams P, Cardozo L, Fal IM et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002; 187: 116-126.
37. Flood H, Malhotra S, O'Connell H, Ritchey M, Bloom D, McGuire E. Long-term results and complications using augmentation cystoplasty in reconstructive urology. Neurourol Urodyn 1995; 14: 297-309.
38. Ghei M, Maraj B, Miller R et al. Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, doubleblind, placebo controlled, crossover trial. J Urol 2005; 174: 1873-1877.
39. Sahai A, Khan M, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 2231-2236.
40. Hirst G, Watkins A, Guerrero K et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007; 69: 69-73.
41. Schmid D, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176: 177-185.
42. De Laet K, Wyndaele J. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005; 43: 397-399.
43. Iswariah H, Stephens J, Rieger N. Randomized prospective controlled trial of lateral internal sphincterotomy versus injections of botulinum toxin for the treatment of idiopathic fissure in ano. Aust N Z J Surgery 2005; 75: 553.
44. Brown S, Matabdu Y, Shorthouse A. A second case of long-term incontinence following botulinum injection for anal fissure. Colorectal Dis 2006; 8: 452-453.
45. Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics 2000; 31: 333-334.